The Best ETFs for 2016

VB Chart
VB Chart

This ETF also offers up a juicy 2.30% dividend yield right now, and that's a higher payout than you can get from large caps.

The combination of a higher yield and small caps' strong history of outperformance could make this ETF a winning choice in 2016.

For contrarians

The strengthening of the U.S. dollar mixed with the collapse in commodity prices has caused many international stocks to take it on the chin. That's doubly true for investors who put money to work in emerging markets, which tend to rely heavily on commodity prices to keep their economies humming.

A quick look at a five-year chart comparing the S&P 500 with the iShares MSCI Emerging Markets ETF shows just had bad the carnage has been:

The ETF has drastically underperformed the U.S. markets in recent years, but if you're a believer in the rise of the global middle class, then now might be a great time to invest in this beaten-down ETF. It holds a huge collection of more than 800 large and midsized companies that make money in the world's emerging economies. Its assets are well diversified around around the globe, offering up exposure to China, India, Brazil, and more.

This fund's recent underperformance has pushed its current yield up to 2.48%, which is near its five-year high and could be a signal of its value.

When the U.S. dollar eventually weakens and commodity prices recover, this fund could be positioned nicely to outperform. In the meantime, its generous dividend yield more than covers its expense ratio of 0.68%.

For risk-tolerant investors

While emerging markets have been sucking wind recently, the biotech sector has been on an absolute tear. One ETF in particular, the SPDR S&P Biotech ETF , has put up an unbelievable five-year performance that's left the S&P 500 in the dust.

So what's the secret to this ETF's success?

As its name implies, the ETF concentrates on the biotech sector. It currently holds a position in 105 companies, many of them small-cap biotechs that on an individual basis carry a very high risk. But this fund's great diversification helps to make investing the in the space more palatable.

One feature I like about this ETF is that it employs an equal-weight strategy, meaning it invests the same amount of capital into each one of its 105 stocks, so if one of its holdings has a monster run -- which can happen easily in the biotech space -- then the entire ETF has a good chance of moving higher.

This fund isn't for the faint of heart, as its investing style makes it very volatile . But if you have a strong stomach and are looking for an ETF to turbo-charge your returns in 2016, this ETF might be a good choice.

The next billion-dollar iSecret

The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .

The article The Best ETFs for 2016 originally appeared on

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More